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Abstract
Background: Limited data are available on the association between vitiligo and autoimmune thyroid disease in
pediatric patients. In addition, reported studies of pediatric patients have been based on a population known to
have vitiligo and subsequently evaluated for the presence of thyroid function abnormalities.
Methods: A retrospective chart review was performed on 333 children who had been followed for thyroid
disorders by endocrinologists at the Yale Pediatric Thyroid Center over the last 5 years for autoimmune thyroid
disease. Demographical and clinical features of patients found to have thyroid disease and vitiligo were recorded.
These studies were approved by the Yale Human Investigation Committee.
Results: Of the total 333 children and adolescents, 9 (2.7%) were noted to have vitiligo. Four patients (44%) had
Graves’ disease and 5 patients (66%) had Hashimoto’s thyroiditis. For patients with Graves’ disease and vitiligo, the
average age of onset of thyroid disease was young at 4 ± 0.7 years, and the diagnosis of vitiligo usually preceded
that of thyroid disease. For children with Hashimoto’s thyroiditis and vitiligo, thyroid disease was diagnosed at an
average age of 13.25 ± 2.8 years.
Conclusion: In our population, 4.6% of children with Graves’ disease and 2.0% of children with Hashimoto’s
thyroiditis had vitiligo. Interestingly, when vitiligo presents with Graves’ disease, it occurs in younger rather than
older children.
Introduction
The association between vitiligo and autoimmune thyroid
disease, especially Hashimoto’s thyroiditis, has been char-
acterized in adults [1-3]. Studies indicate an autoimmune
etiology for vitiligo, and genes have been identified that
cause both vitiligo and autoimmune thyroid disease [1-11].
However, little data are available on the association of viti-
ligo and thyroid disease in children [1-3]. In addition,
reported studies of vitiligo and thyroid disease are based
on studies of children who were identified as having viti-
ligo and subsequently evaluated for the presence of thyroid
function abnormalities [1-7].
Graves’ disease is an autoimmune condition with an
estimated incidence of 1 in 10,000 children [12,13].
Graves’ disease most commonly occurs in teenagers,
and less than 5% of pediatric patients present at less
than 5 years of age [14,15]. Hashimoto’s thyroiditis is
also an autoimmune disease associated with the
presence of anti-thyroid antibodies that can result in
either hypothyroidism or a euthyroid state [16,17]. Like
Graves’ disease, the peak prevalence is in the teenage
years [14,15,18,19]. The incidence of antithyroid antibo-
dies in the pediatric population is as high as 1% in some
studies [16-20].
Both Graves’ disease and Hashimoto’s thyroiditis are
associated with other autoimmune conditions including
diabetes mellitus, inflammatory bowel disease, celiac dis-
ease, autoimmune hepatitis, adrenal insufficiency, and viti-
ligo [14,17-20]. To better characterize the association
between vitiligo and thyroid disease in pediatric patients,
we performed a retrospective analysis of patients diag-
nosed with thyroid disease. We now report the prevalence
and clinical characteristics of children with vitiligo in the
setting of Graves’ disease and Hashimoto’s thyroiditis.
Methods
A retrospective chart review was performed on 333 chil-
dren who had been evaluated for autoimmune thyroid
disorders at the Yale Pediatric Thyroid Center over the
* Correspondence: scott.rivkees@yale.edu
Yale Pediatric Thyroid Center, Department of Pediatrics, Yale University, New
Haven, CT, USA
Prindaville and Rivkees International Journal of Pediatric Endocrinology 2011, 2011:18
http://www.ijpeonline.com/content/2011/1/18
© 2011 Prindaville and Rivkees; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.last 5 years. Patient ages ranged from 1 to 21 years. Stan-
dard clinical diagnostic criteria were used to establish the
diagnosis of Graves’ disease or Hashimoto’s thyroiditis
[21]. As part of routine clinical evaluation, all children
cared for at the Yale Pediatric Thyroid Center are evalu-
ated for eye disease, liver disease, thyroid disease, and
vitiligo. Vitiligo was diagnosed by standard criteria [4],
and confirmed by a dermatologist. In the patients noted
to have vitiligo, demographical and clinical features of
the thyroid disease were recorded. The age at diagnosis
of vitiligo and the timing in relationship to the diagnosis
of thyroid disease were recorded.
Results
Of a total 333 children and adolescents with autoimmune
thyroid disease, 9 (2.7%) were noted to have vitiligo
(Tables 1 and 2). Eighty-seven had Graves’ disease, and 4
of these patients with Graves’ disease (4.6%) had vitiligo.
Two hundred forty-six children had Hashimoto’s thyroidi-
tis, and 5 of these patients (2.0%) had vitiligo.
For the children with Graves’ disease and vitiligo
(Table 1), the average age of onset of thyroid disease
was 4 ± 0.7 years (range 3.5 to 5 years). In 3 of the 4
children, vitiligo presented prior to the thyroid disease.
One child developed vitiligo 6 months after Graves’ dis-
ease was diagnosed. Males and females were represented
equally among the patients with Graves’ disease and
vitiligo.
Of the patients with Hashimoto’s thyroiditis and viti-
ligo (Table 2), all were clinically and biochemically
euthyroid at the time of evaluation with the exception of
one child with an elevated TSH level. Three of the 5
patients (60%) had positive anti-thyroid peroxidase
(TPO) antibodies, and 2 (40%) had anti-thyroglobulin
(Tg) antibodies. The average age at diagnosis of thyroid
disease was 13.25 ± 2.8 years (range 9.75 to 17.25 years).
Three of the children were males and 2 were females.
Discussion
Studying a large cohort of children with Graves’ disease
and Hashimoto’s thyroiditis, we find that 4.6% and 2.0%
of children, respectively, have vitiligo. Interestingly, the
children with vitiligo and Graves’ disease were much
younger than those with Hashimoto’s disease and
vitiligo.
Graves’ disease is rare in the pediatric population, with a
prevalence of about 1 per 10,000 individuals [12,13]. In
children, the peak age of Graves’ disease is 11-15 years,
and it is three to five times more common in females than
in males. In young children, no gender differences have
been found [14,15].
When Hashimoto’s thyroiditis occurs in pediatric
patients, it is most common in adolescence, and is rare
before the age of 3 [19]. The incidence of Hashimoto’si n
adolescence ranges from 1-2% of individuals [18-20]. How-
ever, an NHANES study found that 6.3% of adolescents
from 12 to 19 years of age had positive anti-thyroglobulin
antibodies and 4.8% had anti-thyroid peroxidase antibodies
[16]. Another study of 160 children with antibodies consis-
tent with euthyroid autoimmune thyroiditis had a mean
age of 9.1 years [17].
As T-cell-mediated autoimmune diseases, Graves’ dis-
ease and Hashimoto’s thyroiditis have lymphocytic infiltra-
tion into thyroid parenchyma [10,14,19]. In Graves’
disease, the antibodies bind to thyrotropin receptors, sti-
mulating thyroid hormone production [10,14,19]. In
Hashimoto’s thyroiditis, lymphocytic infiltration leads to
thyroid destruction [10]. Similarly, skin biopsies from viti-
ligo patients show dermal and epidermal lymphocytic infil-
trate, consisting of activated T cells, which are thought to
cause melanocyte destruction [8].
Vitiligo is the most common acquired pigmentary disor-
der in children and adults, with an incidence of approxi-
mately 1% in the general population [1-5]. Vitiligo results
from loss of melanocytes, which leads to well-demarcated
depigmentation in macules or patches on skin, overlying
hair, and/or mucus membranes. Onset of vitiligo prior to
age 20 years occurs in approximately 50% of cases and
before 10 years in approximately 25%, with a nearly equal
gender ratio [1,4-7]. Several etiologies for vitiligo have
been proposed, and significant evidence supports an auto-
immune pathogenesis, with circulating autoantibodies that
target melanocyte antigens and subsequently attack and
destroy melanocytes [1,3-5]. This theory is supported by
the recent identification of genes linked to vitiligo that are
involved in innate immunity [5,6].
Table 1 Patients with Graves’ Disease and Vitiligo
Age of onset thyroid disease
(yrs)
Age of onset vitiligo (yrs) Gender
3.5 Unknown (present at
presentation)
M
3.5 Unknown (present at
presentation)
F
4 4.5 F
5 Unknown (present at
presentation)
M
Table 2 Patients with Hashimoto’s Thyroiditis and
Vitiligo
Age of onset thyroid disease (yrs) Gender TSH
(uU/ml)
9.75 M 2
12 F 5.14
13 M 4.48
14.25 M 25
17.25 F 2.3
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thyroid disease with an 8-25% incidence of autoimmune
thyroid disease in patients with vitiligo [2,3,5,6]. Hashi-
moto’s thyroiditis is seen in the majority of adult patients
with vitiligo and autoimmune thyroid disease [2,3,22]. As
in our cohort, vitiligo was diagnosed before thyroid dis-
ease in most patients in these studies [1,3].
The age of onset of vitiligo has been found to be earlier
in families with a history of multiple autoimmune dis-
eases [22]. This may be at least in part due to variants of
genes including NALP1 that have been associated with
susceptibility to vitiligo and autoimmune thyroid disease
[11]. This gene regulates the immune system, including
activating the inflammatory cascade, and is expressed on
T cells and Langerhans’ cells [11].
Studies have also identified immunogenetic associa-
tions with vitiligo and autoimmune thyroid diseases. Viti-
ligo is associated with HLA-DR4, and thyroid disease is
associated with Class 1 and Class II HLA including HLA-
DR [8-10]. Graves’ disease has been associated with
HLA-DR3 [9,14,20]. In comparison, Hashimoto’st h y r o i -
ditis has not had a consistent HLA-association, but HLA-
DR has been associated [9]. Other studies have shown an
increase in CD4+ T-lymphocytes in addition to an ele-
vated CD4+/CD8+ ratio in vitiligo patients [8], a finding
that is present in patients with autoimmune thyroid dis-
ease [9,10].
Similarly, patients with vit i l i g oa n da tl e a s to n eo t h e r
autoimmune condition, including either Graves’ disease or
Hashimoto’s thyroiditis, have been found to have a cyto-
toxic T lymphocyte antigen-4 (CTLA-4) polymorphism,
which is involved in T cell apoptosis [8-10]. In Graves’ dis-
ease, a specific CTLA-4 polymorphism has been associated
with an early age of onset and severity of presentation [9].
Thus in the future, it will be interesting to characterize the
genetic associations of vitiligo and other autoimmune dis-
eases in the pediatric population.
Overall, our observations of a significant incidence of
vitiligo in children with thyroid disease shows that chil-
dren with thyroid disease should be screened for vitiligo,
especially young children with Graves’ disease. Thyroid
screening is already recommended annually for patients
with vitiligo [1-6]. The occurrence of Graves’ disease
and vitiligo in young children further supports the
notion that the nature of the autoimmune disorder in
the young population differs from that seen in older
children.
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